Skip to main content
. Author manuscript; available in PMC: 2019 Sep 1.
Published in final edited form as: Adv Mater. 2018 Jul 4;30(37):e1707634. doi: 10.1002/adma.201707634

Figure 1.

Figure 1

(a) Schematic illustration of the MIL-101(Fe) nMOF design, its targeted delivery, and anticancer process. (b) Confocal images showing tumor-specific cellular uptake of DOX@TTMOF at different pH. Dot plots (c) and mean fluorescence intensity (d) of quantitative flow cytometry analysis. Tumor volume (e) and body weight (f) changes in H-22 tumor-bearing mice after treatment. Reproduced with permission.[51] Copyright 2015 The Royal Society of Chemistry.